7月29日，GE医疗盘前上涨5.76%，报69.5美元/股，成交额10.8万美元。消息面上，公司于盘前发布第二季度财报，并重申全年调整后每股收益指引区间为4.80至5.00美元，与FactSet一致预期4.88美元基本吻合。
此前公司在一季度因内存芯片、石油及运费成本激增，将全年调整后EPS指引从4.95-5.15美元下调至4.80-5.00美元，当时股价承压。本次重申指引表明成本压力已得到有效管控，业务延续稳健增长态势。公司7月24日已提前披露Q2初步业绩，传递业务加速信号。此外，公司近期签下与Catholic Health价值5亿美元的十年战略合作协议，并在AI影像、新型造影剂等多条创新管线上取得进展，为中长期增长奠定基础。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.